ELI 005
Alternative Names: ELI-005Latest Information Update: 26 Jun 2023
Price :
$50 *
At a glance
- Originator Elicio Therapeutics
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 26 Jun 2023 Discontinued - Preclinical for COVID-2019 infections (Prevention) in USA (Intranasal) (before June 2023) (Elicio Therapeutics Pipeline, June 2023)
- 26 Jun 2023 Discontinued - Preclinical for COVID-2019 infections (Prevention) in USA (SC) (before June 2023) (Elicio Therapeutics Pipeline, June 2023)
- 04 Oct 2022 Preclinical trials in COVID-2019 infections (Prevention) in USA (Intranasal), prior to October 2022